ICAD | iCAD, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.9850 - 2.0800
52 Week Range	1.1800 - 3.78
Beta	1.71
Implied Volatility	208.08%
IV Rank	N/A
Day's Volume	244,304
Average Volume	473,215
Shares Outstanding	26,540,000
Market Cap	54,672,400
Sector	Healthcare
Industry	Medical - Devices
IPO Date	1984-12-13

Valuation
Profitability
Growth
Health
P/E Ratio	-9.81
Forward P/E Ratio	-3.11
EPS	-0.21
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	67
Country	USA
Website	ICAD

icad Inc provides cancer detection, radiation therapy and workflow solutions, primarily computer-aided detection and workflow solutions for breast, prostate and colorectal cancers. Its products include powerlook tomo detection, powerlook density assessment, and vera look. The firm has also developed a technology namely Xoft Axxent electronic brachytherapy system used in the treatment of non-melanoma skin cancer, early-stage breast cancer, and gynecological cancers.

ICAD's peers: PROF, SIBN, SGHT, NVRO, FNA, SSKN, SIEN, AXGN, AIMD, LNSR, AZYO, INVO, NVNO, ESTA, CVRX, SRGA, SRDX, BMRA, MOVE

*Chart delayed

Analyzing fundamentals for ICAD we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ICAD Fundamentals page.

Watching at ICAD technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ICAD Technicals page.